Asparaginase erythrocyte encapsulated - ERYtech Pharma

Drug Profile

Asparaginase erythrocyte encapsulated - ERYtech Pharma

Alternative Names: ERY-001; ERY-ASP; ERYASP; Eryaspase; Erythrocyte-encapsulated L-asparaginase; GRASPA; L-asparaginase loaded erythrocytes

Latest Information Update: 19 Apr 2017

Price : $50

At a glance

  • Originator ERYtech Pharma
  • Class Amidohydrolases; Antineoplastics
  • Mechanism of Action Asparagine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Acute myeloid leukaemia; Acute lymphoblastic leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Pancreatic cancer
  • Preclinical Non-Hodgkin's lymphoma
  • No development reported Haematological malignancies; Solid tumours

Most Recent Events

  • 06 Apr 2017 Phase-II clinical trials in Acute lymphoblastic leukaemia (In infants, In children, In adolescents, In adults) in Denmark (IV) (EudraCT2016-004451-70)
  • 04 Apr 2017 The Nordic society of Paediatric Haematology and Oncology in collaboration with Erytech Pharma plans a phase II trial for Acute lymphoblastic leukaemia in Denmark, Fiinland, Norway, sweden, Iceland, Lithuania and Estonia
  • 27 Mar 2017 Efficacy data from a phase II trial in Pancreatic cancer released by ERYTECH Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top